About this ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is composed of all of the components of the S&P 500® Health Care Index, an index that contains the common stocks of all companies included in the S&P 500® Index that are classified as members of the health care sector, as defined according to the Global Industry Classification Standard (GICS).
Description from the fund data provider · profile as of Aug 27, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | — | — | — | — | — | -52.53% | -33.31% | -15.70% | -2.85% |
| Total return | — | — | — | — | — | -52.46% | -33.24% | -15.51% | -2.67% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Jul 10, 2025. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.40% | Annual cost of a $10,000 investment | $40.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Aug 25, 2026 — portfolio reporting date from the data provider; holdings are not live positions. 64 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | Moderna Inc | MRNA | 4.31% | 258.11K | $35.8M |
| 2 | Charles River Laboratories International Inc | CRL | 2.29% | 63.74K | $19.0M |
| 3 | Veeva Systems Inc | VEEV | 2.17% | 72.51K | $18.0M |
| 4 | IQVIA Holdings Inc | IQV | 2.04% | 65.24K | $17.0M |
| 5 | Bio-Techne Corp | TECH | 1.97% | 226.19K | $16.4M |
| 6 | Regeneron Pharmaceuticals Inc | REGN | 1.97% | 19.74K | $16.4M |
| 7 | Amgen Inc | AMGN | 1.88% | 35.16K | $15.6M |
| 8 | Abbott Laboratories | ABT | 1.87% | 133.07K | $15.5M |
| 9 | Baxter International Inc | BAX | 1.86% | 584.47K | $15.5M |
| 10 | Thermo Fisher Scientific Inc | TMO | 1.86% | 24.60K | $15.5M |
| 11 | Becton Dickinson & Co | BDXA | 1.84% | 80.25K | $15.3M |
| 12 | Merck & Co Inc | MRK | 1.81% | 99.65K | $15.0M |
| 13 | Labcorp Holdings Inc | LH | 1.80% | 44.18K | $15.0M |
| 14 | Vertex Pharmaceuticals Inc | VRTX | 1.79% | 27.19K | $14.9M |
| 15 | Mettler-Toledo International Inc | MTD | 1.77% | 10.52K | $14.7M |
| 16 | Dexcom Inc | DXCM | 1.74% | 158.76K | $14.5M |
| 17 | Universal Health Services Inc | UHS | 1.74% | 81.94K | $14.5M |
| 18 | Incyte Corp | INCY | 1.73% | 112.62K | $14.4M |
| 19 | Revvity Inc | PKI | 1.73% | 117.17K | $14.4M |
| 20 | Bristol-Myers Squibb Co | BMY | 1.73% | 213.53K | $14.4M |
| 21 | Gilead Sciences Inc | GILD | 1.72% | 97.67K | $14.3M |
| 22 | ResMed Inc | RMD | 1.71% | 61.36K | $14.3M |
| 23 | Quest Diagnostics Inc | DGX | 1.71% | 58.19K | $14.2M |
| 24 | AbbVie Inc | ABBV | 1.68% | 52.78K | $14.0M |
| 25 | Danaher Corp | DHR | 1.67% | 64.59K | $13.9M |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 0.08% | Paid (last 12 months) | $0.2318 |
| Frequency | Quarterly | SEC yield | Not provided by our data source — see the issuer page |
| Last ex-date | Jun 22, 2026 | Last payment | $0.0627 |
| Growth 1Y | +40.24% | Growth 3Y / 5Y (ann.) | +7.93% / +13.17% |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Jun 22, 2026 | — | — | $0.0627 |
| Mar 23, 2026 | — | — | $0.0561 |
| Dec 22, 2025 | — | — | $0.0530 |
| Sep 22, 2025 | — | — | $0.0599 |
| Jun 23, 2025 | — | — | $0.0555 |
| Mar 24, 2025 | — | — | $0.0551 |
| Sep 23, 2024 | — | — | $0.0547 |
| Jun 24, 2024 | — | — | $0.0508 |
| Mar 18, 2024 | — | — | $0.0459 |
| Dec 18, 2023 | — | — | $0.0499 |
| Sep 18, 2023 | — | — | $0.0479 |
| Jun 20, 2023 | — | — | $0.0511 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
Liquidity
| Volume today | 8.41K | Average volume | 8.12K |
| AUM | $960.7M | Premium/Discount | +885.11% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV — an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source — review them before investing.
Latest News for RYH
No articles mention this fund directly in the last 7 days — showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.
RYH